Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF PartnersPRNewsWire • 04/06/26
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total ProceedsGlobeNewsWire • 04/02/26
Entera Bio Announces Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/27/26
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with OsteoporosisGlobeNewsWire • 03/04/26
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key MilestonesGlobeNewsWire • 02/09/26
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis InnovationGlobeNewsWire • 12/23/25
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)GlobeNewsWire • 12/22/25
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare ConferenceGlobeNewsWire • 11/18/25
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal WomenGlobeNewsWire • 10/23/25
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual MeetingGlobeNewsWire • 10/16/25
Entera Bio Unveils Promising PK Data for First Oral GLP-2 TherapyZacks Investment Research • 09/18/25
Entera Bio Announces Second Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 08/08/25
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with OsteoporosisGlobeNewsWire • 07/28/25
Entera Bio Announces First Quarter 2025 Financial Results and Business UpdatesGlobeNewsWire • 05/09/25
Entera Bio Announces Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/28/25
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic DisordersGlobeNewsWire • 03/17/25
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 01/27/25
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic DisordersGlobeNewsWire • 09/25/24
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 09/18/24